Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States

C. Iglesias-Lopez, Merce Obach, A. Vallano, A. Agustí, Joel Montané Mogas

Producció científica: Article en revista indexadaArticleAvaluat per experts

7 Cites (Scopus)

Resum

An environmental risk assessment (ERA) consists of an analysis of the risks to human health and the environment that a medicinal product may cause due to its release during clinical development or after entering the market. Regulators in European Union (EU) and the United States (US) require that advanced therapy medicinal products (ATMPs) that are also genetically modified organisms (GMOs) undergo an ERA in order to be approved for marketing authorization. This work aims to review the regulatory issues that need to be taken into consideration for carrying out an ERA, comparing the EU and the US. The European regulatory framework for environmental procedures and the dissimilarities in its implementation across the Member States and its implications at a logistical level are analyzed in detail. In addition, this review provides a brief insight into the non-clinical and clinical assessments that should be carried out during the development of the product in order to conduct a successful ERA, and thus facilitate its marketing authorization and post-marketing monitoring. Finally, the need for a European harmonization regarding environmental procedures for ATMPs is discussed.
Idioma originalAnglès
Pàgines (de-a)580-596
Nombre de pàgines17
RevistaCritical Reviews in Toxicology
Volum49
Número7
Estat de la publicacióPublicada - 17 de des. 2019

Fingerprint

Navegar pels temes de recerca de 'Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States'. Junts formen un fingerprint únic.

Com citar-ho